The price of Sanofi ADR (NASDAQ: SNY) closed at $47.29 in the last session, down -1.17% from day before closing price of $47.85. In other words, the price has decreased by -$0.56 from its previous closing price. On the day, 2931317 shares were traded.
Ratios:
We take a closer look at SNY’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.30 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.81. For the most recent quarter (mrq), Quick Ratio is recorded 0.87 and its Current Ratio is at 1.27. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.22.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on January 23, 2024, initiated with a Equal-Weight rating and assigned the stock a target price of $55.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SNY now has a Market Capitalization of 117.77B and an Enterprise Value of 127.98B. As of this moment, Sanofi’s Price-to-Earnings (P/E) ratio for their current fiscal year is 20.36, and their Forward P/E ratio for the next fiscal year is 9.91. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.26. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.54 while its Price-to-Book (P/B) ratio in mrq is 1.45. Its current Enterprise Value per Revenue stands at 2.76 whereas that against EBITDA is 10.15.
Stock Price History:
Over the past 52 weeks, SNY has reached a high of $57.82, while it has fallen to a 52-week low of $42.63. The 50-Day Moving Average of the stock is 49.09, while the 200-Day Moving Average is calculated to be 50.91.
Shares Statistics:
According to the various share statistics, SNY traded on average about 1.76M shares per day over the past 3-months and 1.8M shares per day over the past 10 days. A total of 2.50B shares are outstanding, with a floating share count of 2.50B. Insiders hold about 0.02% of the company’s shares, while institutions hold 9.90% stake in the company. Shares short for SNY as of Feb 15, 2024 were 4.06M with a Short Ratio of 2.30, compared to 5.65M on Jan 12, 2024.
Dividends & Splits
The forward annual dividend rate for SNY is 1.90, which was 3.76 in the trailing 12 months. Against a Trailing Annual Dividend Yield of 7.86%, it implies a Forward Annual Dividend Yield of 4.02%. The stock’s 5-year Average Dividend Yield is 3.73. The current Payout Ratio is 39.20% for SNY, which recently paid a dividend on Jun 23, 2023 with an ex-dividend date of May 30, 2023. Stock splits for the company last occurred on Sep 30, 2013 when the company split stock in a 5:1 ratio.
Earnings Estimates
The company has 1 analysts who recommend its stock at the moment. On average, analysts expect EPS of $1.92 for the current quarter, with a high estimate of $1.92 and a low estimate of $1.92, while EPS last year was $1.16. The consensus estimate for the next quarter is $1.8, with high estimates of $1.8 and low estimates of $1.8.
Analysts are recommending an EPS of between $9.61 and $4.2 for the fiscal current year, implying an average EPS of $7.82. EPS for the following year is $9.23, with 11 analysts recommending between $10.82 and $5.21.
Revenue Estimates
According to 3 analysts, the current quarter’s revenue is expected to be $11.47B. It ranges from a high estimate of $11.87B to a low estimate of $11.22B. As of the current estimate, Sanofi ADR’s year-ago sales were $11.33B, an estimated increase of 1.30% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $11.68B, an increase of 3.90% over than the figure of $1.30% in the same quarter last year. There is a high estimate of $11.92B for the next quarter, whereas the lowest estimate is $11.49B.
A total of 13 analysts have provided revenue estimates for SNY’s current fiscal year. The highest revenue estimate was $54.03B, while the lowest revenue estimate was $47.84B, resulting in an average revenue estimate of $50.46B. In the same quarter a year ago, actual revenue was $46.57B, up 8.40% from the average estimate. Based on 13 analysts’ estimates, the company’s revenue will be $53.91B in the next fiscal year. The high estimate is $57.27B and the low estimate is $51.95B. The average revenue growth estimate for next year is up 6.90% from the average revenue estimate for this year.
